Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00814281 · ClinicalTrials.gov registry record · NA
Airborne Ultrafine and Fine Particulate Matter: A Cause for Endothelial Dysfunction in Man?
A NA study, sponsored by Marywood University.
- Completed
- Registry status
- NA
- Development phase
- 24
- Enrollment target
NCT00814281 is a NA study that has completed, run by Marywood University. The registered enrollment target is 24 participants.
The verdict
NCT00814281, a NA study, has completed, sponsored by Marywood University.
- COMPLETED
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to examine biological pathways of altered blood vessel function resulting from breathing airborne particulate. Blood artery function in healthy men will be measured after particulate exposure either on placebo or on an asthma medication that stops production of an inflammatory biological agent. Lung and blood profiles will be obtained before and after exposure to exhaust fumes. We believe that the inflammatory agent produced by the lungs from breathing these particles causes abnormal artery function.
Interventions
- DRUG Montelukast
- OTHER placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2007-05 |
| Est. Completion | 2009-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00814281
The ClinicalTrials.gov registry entry for NCT00814281 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Marywood University, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Montelukast is the first listed.
NCT00814281 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00814281 about?
NCT00814281 is a clinical study titled "Airborne Ultrafine and Fine Particulate Matter: A Cause for Endothelial Dysfunction in Man?". The purpose of this study is to examine biological pathways of altered blood vessel function resulting from breathing airborne particulate. Blood artery function in healthy men will be measured after particulate exposure either on placebo or on an asthma medication that stops production of an inflam...
What is the current status of trial NCT00814281?
This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2007-05. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00814281?
The interventions under investigation include: Montelukast (DRUG), placebo (OTHER).
Who is sponsoring clinical trial NCT00814281?
This trial is sponsored by Marywood University, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.